Showing results (141-150 of 187) with videos related to

Sort By:
Pageof 19
International Journal of Clinical Oncology|August 1, 2025
First-line pembrolizumab plus chemotherapy for participants in Japan with gastric or gastroesophageal junction adenocarcinoma: subgroup analysis of the phase 3 KEYNOTE-859 studyHisateru Yasui, Masaki Aizawa, Kensei Yamaguchi, et al.
Japanese Journal of Clinical Oncology|March 6, 2026
Impact of prior immune checkpoint inhibitor on trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory analysis of the EN-DEAVOR studyYukiya Narita, Hisato Kawakami, Koki Nakanishi, et al.
Cancer Chemotherapy and Pharmacology|February 27, 2019
A study of second-line irinotecan plus cisplatin vs. irinotecan alone in platinum-naïve patients with early relapse of gastric cancer refractory to adjuvant S-1 monotherapy: exploratory subgroup analysis of the randomized phase III TRICS trialKazuhiro Nishikawa, Kenta Murotani, Kazumasa Fujitani, et al.
Cancer Medicine|September 24, 2024
Real-world assessment of comprehensive genome profiling impact on clinical outcomes: A single-institution study in JapanKei Kunimasa, Naotoshi Sugimoto, Tomoyuki Yamasaki, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|March 13, 2026
Long-term survival outcomes from a phase II trial of perioperative capecitabine plus oxaliplatin for advanced gastric cancer with extensive lymph node metastases: OGSG 1701Shunji Endo, Yutaka Kimura, Naotoshi Sugimoto, et al.
European Journal of Cancer (Oxford, England : 1990)|May 8, 2020
Differences in disease status between patients with progression after first-line chemotherapy versus early relapse after adjuvant chemotherapy who undergo second-line chemotherapy for gastric cancer: Exploratory analysis of the randomized phase III TRICS trialKazuhiro Nishikawa, Kenta Murotani, Kazumasa Fujitani, et al.
International Journal of Clinical Oncology|July 8, 2011
Predicting the effects of chemoradiotherapy for squamous cell carcinoma of the esophagus by induction chemotherapy response assessed by positron emission tomography: toward PET-response-guided selection of chemoradiotherapy or esophagectomyRyu Ishihara, Sachiko Yamamoto, Hiroyasu Iishi, et al.
The Lancet. Oncology|December 8, 2015
S-1 plus leucovorin versus S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin in patients with advanced gastric cancer: a randomised, multicentre, open-label, phase 2 trialShuichi Hironaka, Naotoshi Sugimoto, Kensei Yamaguchi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 15, 2022
Trastuzumab Deruxtecan in Anti-Human Epidermal Growth Factor Receptor 2 Treatment-Naive Patients With Human Epidermal Growth Factor Receptor 2-Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II TrialKensei Yamaguchi, Yung-Jue Bang, Satoru Iwasa, et al.
Thoracic Cancer|September 13, 2022
Clinical application of comprehensive genomic profiling panel to thoracic malignancies: A single-center retrospective studyKei Kunimasa, Naotoshi Sugimoto, Takahisa Kawamura, et al.
Pageof 19